The role of pulmonary function testing in pulmonary fibrosis

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 5, 2000, Pages 404-410

  Flaherty, Kevin R ^a   Martinez, Fernando J ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG PARENCHYMA; META ANALYSIS; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

EID: 0033873108     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200009000-00003     Document Type: Review

References (63)

1. 1 Schwarz MI: Approach to the understanding, diagnosis, and mangaement of interstitial lung disease. In Interstitial Lung Disease. Edited by Schwarz M and King T Jr. Hamilton, ON: B.C. Decker, Inc.; 1998:3-30.
2. 2 Coultas DB, Zumwalt RE, Black WC, et al.: The epidemiology of interstitial lung diseases. Am J Respir Care Med 1994, 150:967-972.
3. 3 O'Donnell DE: Physiology of interstitial lung disease. In Interstitial Lung Disease. Edited by Schwarz M and King T Jr. Hamilton, ON: B.C. Decker, Inc.; 1998:51-70.
4. 4 Cherniack RM, Colby TV, Flint A, et al: Correlation of structure and functions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995, 151:1180-1188.
5. 5 Doherty MJ, Pearson MG, O'Grady EA, et al: Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997, 52:998-1002.
6. 6 Dunn TL, Watters LC, Hendrix C, et al: Gas exchange at a given degree of volume restriction is different in sarcoidosis and idiopathic pulmonary fibrosis. Am J Med 1988, 85:221-224.
7. 7 Keogh BA, Lakatos E, Price D, et al: Importance of the lower respiratory tract in oxygen transfer. Exercise testing in patients with interstitial and destructive lung diseases. Am Rev Respir Dis 1984, 129 (Suppl):S76-S80.
8. 8 Robertsone HT: Clinical application of pulmonary function and exercise tests in the management of patients with interstitial lung disease. Sem Respir Crit Care Med 1994, 15:1-9.
9. 9 Gaensler EA, Carrington CB, Coutu RE, et al: Radiographic-physiologic-pathologic correlations in interstitial pneumonias. Prog Respir Res 1975, 8:223-241.
10. 10 Austrian R, McClement JH, Renzetti AD, et al: Clinical and physiologic features of some types of pulmonary diseases with impairment of alveolar-capillary diffusion. Am J Med 1951, 11:667-685.
11. 11 Fulmer JD, Roberts WC, von Gael ER, et al. Morphologic-physiologic correlates of the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. J Clin Invest 1979, 63:65-76
12. 12 Risk C, Epler GR, Gaensler EA: Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. Chest 1984, 85:69-74.
13. 13 Hansen JE, Wasserman K: Pathophysiology of activity limitation in patients with interstitial lung disease. Chest 1996, 109:1566-76.
14. 14 Reynolds HY: Diagnostic and management strategies for diffuse interstitial lung disease. Chest 1998, 113:192-202.
15. 15 Johnston IDA, Prescott BJ, Chalmers JC, et al: British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 1997, 52:38-44.
16. 16 Epler GR, McLoud TC, Gaensler EA, et al: Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med 1978, 298:934-939.
17. 17 Orens JB, Kazerooni EA, Martinez FJ, et al: The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy. A prospective study. Chest 1996, 108:109-115.
18. 18 Crystal RG, Fulmer JD, Roberts WC, et al: Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Int Med 1976, 85:769-788.
19. 19 Jazek V, Fucik J, Michaljanic A, et al: The prognostic significance of functional tests in kryptogenic fibrosing alveolitis. Bull Eur Physiolpathol Respir 1980, 16:711-720.
20. 20 Williams R, Hugh-Jones P: The significance of lung function changes in asbestosis. Thorax 1960, 15:109-119.
21. 21 Bohadana AB, Peslin R, Poncelet B, et al: Lung mechanical properties in silicosis and silicoanthracosis. Bull Eur Physiopathol Respir 1980, 16:521-532.
22. 22 William JV: Pulmonary function in patients with farmer's lung. Thorax 1963, 18:255-263.
23. 23 Augusti AGN, Roca J, Rodriguez-Roisin R, et al: Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. Eur Respir J 1988, 1:510-516.
24. 24 Katzenstein ALA, Myers JL: Idiopathic pulmonary fibrosis. Clincal relevance of pathologic classification. Am J Respir Crit Care Med 1998, 157:1301-1315.
25. 25 Bjoraker JA, Ryu JH, Edwin MK, et al: Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 157:199-203.
26. 26 Nagai S, Kitaichi M, Itoh H, et al: Idiopathic nonspecific interstitial pneumonia/fibrosis; comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J 1998, 12:1010-1019.
27. 27 Cottin V, Dosbeck Av, Revel D, et al: Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. Am J Respir Crit Care Med 1998, 1286-1293.
28. 28 Daniil ZD, Gilchrist FC, Nicholson AG, et al: A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999, 160:899-905. Cohort study demonstrating improved survival in patients with NSIP compared with those with UIP.
29. 29 American Thoracic Society: Idiopathic pulmonary fibrosis: Diagnosis and treatment. Am J Respir Crit Care Med 2000, 161:646-664. Excellent review of diagnostic criteria and therapeutic options in UIP.
30. 30 Kirtland SH, Winterbauer RH: Pulmonary function tests abd idiopathic pulmonary fibrosis. Simple may be better. Chest 1997, 111:7-8.
31. 31 Carrington CB, Gaensler EA, Coutu RE, et al: Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978, 298:801-809.
32. 32 Turner-Warwick M, Burrows B, Johnson A: Cryptogenic fibrosing alveolitis: clinical features and their influence on survivial. Thorax 1980, 35:171-180.
33. 33 Fulmer JD, Roberts WD, Crystal RG: Diffuse fibrotic lung disease: a correlative study. Chest 1976, 69(suppl):263-265.
34. 34 Keogh BA, Crystal RG: Pulmonary function testing in interstitial pulmonary disease. What does it tell us? Chest 1980, 78:856-865.
35. 35 Kanengiser LC, Rapoport DM, Epstein H, et al: Volume adjustment of mechanics and diffusion in interstitial lung disease. Lack of clinical significance. Chest 1989, 96:1036-1042.
36. 36 Watters LC, King TE, Schwarz MI, et al: A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986, 133:97-103.
37. 37 Chinet T, Jaubert F, Dusser D, et al: Effects of inflammation and fibrosis on pulmonary function in diffuse lung fibrosis. Thorax 1990, 45:675-678.
38. 38 Wells AU, King AD, Rubens MB, et al: Lone cryptogenic fibrosing alveolitis: A functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997, 155:1367-1375.
39. 39 Xaubet A, Agusti C, Luburich P, et al: Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 158:431-436.
40. 40 Brantly M, Avila NA, Shotelersuk V, et al: Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansk-Pudlak Syndrome, due to mutation in HPS-1. Chest 2000, 117:129-136.
41. 41 Hubbard R, Johnston I, Britton J: Survival in patients with cryptogenic fibrosing alveolitis. A population-based cohort study. Chest 1998, 113:396-400.
42. 42 Erbes R, Schaberg T, Loddenkemper R: Lung function tests in patients with idiopathic fibrosis. Are they helpful for predicting outcome? Chest 1997, 111:51-57.
43. 43 Raghu G, Johnson WC, Lockhart D, et al: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, Pirfenidone. Results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999, 159:1060-1069.
44. 44 Panos RJ, Mortenson RL, Niccoli SA, et al: Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990, 88:396-404.
45. 45 Wells AU, Hansell DM, Rubens MB, et al: The predictive value of appearances on thin-selection computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993, 148:1076-1082.
46. 46 Gay SE, Kazerooni EA, Toews GB, et al: Idiopathic pulmonary fibrosis: Predicting response to therapy and survival. Am J Respir Crit Care Med 1998, 157:1063-1072.
47. 47 American Thoracic Society: Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991, 144:1202-1218.
48. 48 American Thoracic Society: Single-breath carbon monoxide diffusing capacity (transfer factor)-recommendations for a standard technique. 1995 update. Am Rev Respir Crit Care Med 1995, 152:2185-2198.
49. 49 Kangalee KM, Abboud RT: Interlaboratory abd intralaboratory variability in pulmonary function testing. A 13-year study using a normal biological control. Chest 1992, 101:88-92.
50. 50 Crapo RO: Carbon monoxide diffusing capacity (transfer factor): Sem Respir Crit Care Med 1998, 19:335-347.
51. 51 Douglas WW, Ryu JH, Swensen SJ, et al: Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Am J Respir Crit Care Med 1998, 158:220-225.
52. 52 Hanson D, Winterbauer RH, Kirtland SH, et al: Changes in pulmonary function tests results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995, 108:305-310.
53. 53 Johnson MA, Kwan S, Snell NJC, et al: Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989, 44:280-288.
54. 54 Raghu G, DePaso WJ, Cain K, et al.: Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991, 144:291-296.
55. 55 Rudd RM, Haslam PL, Turner-Warwick M: Cryptogenic fibrosing alveolitis: Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981, 124:1 -8.
56. 56 Stack BHR, Choo-Kang YFI, Heard BE: The prognosis of cryptogenic fibrosing alveolitis. Thorax 1972, 27:535-542.
57. 57 Turner-Warwick M, Burrows B, Johnson A: Cryptogenic fibrosing alveolitis: response to corticosteroid therapy and its effect on survival. Thorax 1980, 35:593-599.
58. 58 Marcinìuk DD, Watts RE, Gallagher CG: Reproducibility of incremental maximal cycle ergometer testing in patients with restrictive lung disease. Thorax 1993, 48:894-898.
59. 59 Augusti C, Xaubet A, Agusti AGN, et al.: Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up. Eur Respir J 1994, 7:643-650.
60. 60 van Oortegem K, Wallaert B, Marquette CH, et al.: Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur Respir J 1994, 7:1950-1957.
61. 61 Watters LC, Schwarz MI, Cherniack RM, et al.: Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology abd clinical response to therapy. Am Rev Respir Dis 1997, 135:696-704.
62. 62 Tukiainen P, Taskinen E, Holsti P, et al.: Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983, 38:349-355.
63. 63 Schwartz DA, Helmers RA, Galvin JR, et al.: Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994, 149:450-454.